Exploration of oxidized phosphocholine profile in non-small-cell lung cancer.

Autor:	Godzien J; Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland., Lopez-Lopez A; Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain., Sieminska J; Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland., Jablonowski K; Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland., Pietrowska K; Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland., Kisluk J; Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland., Mojsak M; Independent Laboratory of Molecular Imaging, Medical University of Bialystok, Bialystok, Poland., Dzieciol-Anikiej Z; Department of Rehabilitation, Medical University of Bialystok, Bialystok, Poland., Barbas C; Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Boadilla del Monte, Spain., Reszec J; Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland., Kozlowski M; Department of Thoracic Surgery, Medical University of Bialystok, Bialystok, Poland., Moniuszko M; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland., Kretowski A; Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland., Niklinski J; Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland., Ciborowski M; Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
Jazyk:	angličtina
Zdroj:	Frontiers in molecular biosciences [Front Mol Biosci] 2024 Jan 15; Vol. 10, pp. 1279645. Date of Electronic Publication: 2024 Jan 15 (Print Publication: 2023).
DOI:	10.3389/fmolb.2023.1279645
Abstrakt:	Introduction: Lung cancer is one of the most frequently studied types of cancer and represents the most common and lethal neoplasm. Our previous research on non-small cell lung cancer (NSCLC) has revealed deep lipid profile reprogramming and redox status disruption in cancer patients. Lung cell membranes are rich in phospholipids that are susceptible to oxidation, leading to the formation of bioactive oxidized phosphatidylcholines (oxPCs). Persistent and elevated levels of oxPCs have been shown to induce chronic inflammation, leading to detrimental effects. However, recent reports suggest that certain oxPCs possess anti-inflammatory, pro-survival, and endothelial barrier-protective properties. Thus, we aimed to measure the levels of oxPCs in NSCLC patients and investigate their potential role in lung cancer. Methods: To explore the oxPCs profiles in lung cancer, we performed in-depth, multi-level metabolomic analyses of nearly 350 plasma and lung tissue samples from 200 patients with NSCLC, including adenocarcinoma (ADC) and squamous cell carcinoma (SCC), the two most prevalent NSCLC subtypes and COPD patients as a control group. First, we performed oxPC profiling of plasma samples. Second, we analyzed tumor and non-cancerous lung tissues collected during the surgical removal of NSCLC tumors. Because of tumor tissue heterogeneity, subsequent analyses covered the surrounding healthy tissue and peripheral and central tumors. To assess whether the observed phenotypic changes in the patients were associated with measured oxPC levels, metabolomics data were augmented with data from medical records. Results: We observed a predominance of long-chain oxPCs in plasma samples and of short-chain oxPCs in tissue samples from patients with NSCLC. The highest concentration of oxPCs was observed in the central tumor region. ADC patients showed higher levels of oxPCs compared to the control group, than patients with SCC. Conclusion: The detrimental effects associated with the accumulation of short-chain oxPCs suggest that these molecules may have greater therapeutic utility than diagnostic value, especially given that elevated oxPC levels are a hallmark of multiple types of cancer. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Godzien, Lopez-Lopez, Sieminska, Jablonowski, Pietrowska, Kisluk, Mojsak, Dzieciol-Anikiej, Barbas, Reszec, Kozlowski, Moniuszko, Kretowski, Niklinski and Ciborowski.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu